What is the story about?
The U.S. Food and Drug Administration has approved a new higher-dose version of Wegovy, an obesity treatment developed by Novo Nordisk, aimed at helping
users achieve greater weight loss and maintain their results. The newly sanctioned 7.2-milligram dosage, which is administered as a weekly injection, increases from the previous maximum dose of 2.4 milligrams, marking a significant development in obesity treatment options.
Accelerated Approval Process
This new formulation underwent an expedited review process through the FDA's fast-track drug evaluation program, receiving approval just 54 days after the review request was initiated, according to agency officials.The higher-dose Wegovy is expected to be available in U.S. pharmacies starting in April, with pricing details to be revealed at that time.
Clinical Study Results
Wegovy HD, as the higher-dose version is known, demonstrated significant efficacy in clinical trials, with participants losing approximately 19% of their body weight, or nearly 47 pounds, over a period of 17 months. This is a notable improvement compared to the 16% weight loss, or 39 pounds, seen with the lower dosage.The need for this higher dosage arose from findings indicating that some patients did not achieve their desired therapeutic outcomes with the 2.4-milligram dose, as published in the medical journal Lancet Diabetes & Endocrinology.
Expert Opinions
Dr. Jody Dushay, an endocrinologist at Harvard Medical School, expressed support for the new dosage, stating it could benefit individuals who are already on the lower dose but have not experienced optimal weight loss. She also noted its potential usefulness for patients who do not respond sufficiently to Eli Lilly's Zepbound, another obesity medication.However, the study highlighted that side effects, including nausea, vomiting, and constipation, were reported by over 70% of participants using the higher dose, compared to more than 60% for the lower dose and about 43% for those receiving a placebo.
Safety and Side Effects
Additionally, about 23% of participants taking the higher dose experienced a condition characterized by unpleasant skin sensations, compared to 6% for the lower dose and less than 1% for the placebo group. Serious adverse events were reported in nearly 7% of those on the 7.2-milligram dose, compared to approximately 11% for the 2.4-milligram dose.Dr. Dushay remarked on the significant increase in dosage, emphasizing the importance of monitoring real-world side effects as opposed to those observed in clinical settings.
